Buy TB-500 (Body Pharm) in South Africa — Research Guide & Protocol Reference (2026)
TB-500 is a synthetic acetylated heptapeptide (Ac-LKKTETQ) corresponding to the active actin-binding region of full-length Thymosin Beta-4, studied as a research peptide for soft-tissue repair, angiogenesis and cell-migration effects. JCSG.org stocks Body Pharm TB-500 for South African researchers — check the current price and order directly via the buy box above, or browse the full TB-500 product range on JCSG.org.
This guide consolidates the mechanistic split between TB-500 and full Tβ4, a sourced dosage-protocol table, and a side-effect risk matrix benchmarked against the 2026 American Journal of Sports Medicine injectable-peptide primer. The South African regulatory position is addressed directly so you can make an informed purchasing decision on JCSG.org today.
Key takeaways
- TB-500 is a 7-amino-acid synthetic fragment of Thymosin Beta-4, not equivalent to the full 43-residue protein.
- All reported benefits — wound healing, tendon recovery, inflammation reduction — derive from preclinical animal studies of the parent molecule; no controlled human trials exist for the Ac-LKKTETQ fragment as of 2026.
- Research-grade dosage protocols range from 2 to 10 mg per injection across loading and maintenance phases.
- Short-term side effects are predominantly injection-site reactions; long-term safety data is absent.
- Body Pharm TB-500 on JCSG.org is manufactured to research-grade purity standards — see the current price in the buy box above and order now.
- No peer-reviewed study has validated co-administration of TB-500 with BPC-157 or GHK-Cu as of 2026, though these are frequently paired in research protocols.
Ready to order Body Pharm TB-500 for your South African research programme?
Check the live price in the buy box above and add to cart — or view all TB-500 products on JCSG.org. Fast local dispatch, Body Pharm quality.
What is TB-500? A plain-language definition
TB-500 is a synthetic N-acetylated heptapeptide with the sequence Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (Ac-LKKTETQ), corresponding to amino acids 17 to 23 of endogenous Thymosin Beta-4 (Tβ4). It is sold as a research-only compound and is not registered as a medicine by SAHPRA, the FDA, or the EMA as of 2026.
The featured definition
TB-500 is a synthetic 7-amino-acid fragment (Ac-LKKTETQ) of the 43-residue protein Thymosin Beta-4, isolated because this short sequence carries the actin-binding LKKTET motif believed to drive Tβ4's cell-migration and repair signalling. Unlike full Tβ4, TB-500 is chemically synthesised, lacks the remaining 36 residues, and has no approved human indication. Body Pharm's formulation, available on JCSG.org, is produced to research-grade purity specifications.
Why this specific fragment is isolated
The LKKTET motif within residues 17 to 23 was mapped in pre-2020 biochemistry literature as the region responsible for sequestering G-actin monomers — the proposed mechanistic basis for Tβ4's effects on cell motility and wound repair. Synthesising only the heptapeptide costs less than producing recombinant full-length Tβ4 because solid-phase peptide synthesis scales more efficiently for short chains, and it concentrates the putative active site into a single fragment.
Why the N-terminal acetyl group matters
Acetylation of the N-terminal leucine blocks aminopeptidase cleavage, extending plasma half-life compared with the unmodified peptide because the enzyme cannot recognise the modified terminus. Vendor catalogues and PubChem records for Ac-LKKTETQ list molecular weights in the ~826 to 830 g/mol range depending on whether the C-terminus is a free acid or amide, which matters when calculating molar doses from a 2 mg vial.
TB-500 sits within a small cluster of peptides South African researchers commonly investigate for tissue repair, alongside BPC-157 and the copper tripeptide GHK-Cu. All three are available as Body Pharm products on JCSG.org.
TB-500 vs. Thymosin Beta-4: why use the fragment?
The fragment is used because it concentrates Tβ4's putative actin-sequestering activity into a shorter, cheaper, more soluble peptide that is easier to synthesise reproducibly than the full 43-residue protein. The trade-off is that TB-500 omits other Tβ4 domains with their own biological signatures, most notably the N-terminal AcSDKP tetrapeptide associated with anti-fibrotic and haematopoietic effects.
Side-by-side comparison
| Property | TB-500 (Ac-LKKTETQ) | Full Thymosin Beta-4 |
|---|---|---|
| Amino acid length | 7 residues | 43 residues |
| Molecular weight | ~826–830 Da | ~4,963 Da |
| LKKTET actin-binding motif | Yes (residues 17–23 of Tβ4) | Yes |
| AcSDKP anti-fibrotic tetrapeptide (1–4) | No | Yes |
| Synthetic reproducibility | High (SPPS, 7-mer) | Moderate (recombinant or long SPPS) |
| N-terminal acetylation | Yes, by design | Native to Tβ4 |
| Human regulatory status (SA, US, EU, 2026) | Unregistered research peptide | No SAHPRA registration; limited pilot human trials |
| Available on JCSG.org (Body Pharm) | Yes — order here | Not stocked |
What the fragment keeps, and what it loses
Ac-LKKTETQ retains the LKKTET actin-binding motif intact — the entire rationale for the cut-down design. No 2023–2026 peer-reviewed paper has re-demonstrated actin binding for Ac-LKKTETQ specifically as a standalone molecule, and current sports-medicine reviews still cite the older Tβ4 work rather than fragment-specific data.
What TB-500 loses is the rest of the molecule. AcSDKP (residues 1–4) circulates as an independent bioactive peptide with documented anti-fibrotic and erythropoietic activity, and that activity is not reproduced by the 17–23 fragment. The C-terminal region of Tβ4 has also been implicated in separate angiogenic and immunomodulatory signalling that LKKTETQ cannot mimic.
How TB-500 works: mechanisms in research
TB-500 is studied for three interlinked mechanisms: actin sequestration enabling cell migration, upregulation of angiogenic signalling, and downregulation of pro-inflammatory cytokines in wound-healing models. All three derive from preclinical in vitro and animal work on the LKKTET-containing parent peptide Tβ4.
Actin sequestration and cell migration
TB-500 promotes cell migration because the LKKTET motif binds monomeric G-actin and modulates the G-actin/F-actin equilibrium that governs cytoskeletal reorganisation. In Tβ4 biochemistry this sequestration frees migrating cells (keratinocytes, endothelial cells, myoblasts) to extend lamellipodia and traverse a wound bed.
Angiogenesis and VEGF signalling
TB-500 is associated with angiogenesis because preclinical Tβ4 models show upregulation of VEGF receptor expression and increased endothelial tube formation in vitro and in vivo. Human randomised controlled trial data confirming this for Ac-LKKTETQ specifically does not exist as of 2026.
Anti-inflammatory signalling
TB-500's anti-inflammatory effect in preclinical models is attributed to downregulation of NF-κB signalling and reduced expression of pro-inflammatory cytokines such as TNF-α and IL-1β in injured tissue. These mechanisms underpin the recovery profile that makes TB-500 a leading choice for South African tissue-repair research programmes.
TB-500 benefits: what research shows in 2026
Every reported benefit currently sits at the preclinical or anecdotal tier, with no large-scale human randomised controlled trial confirming efficacy of the Ac-LKKTETQ fragment as of 2026. South African researchers should treat the benefit profile as observed in animal and in vitro models. See current pricing and stock on JCSG.org's TB-500 product page.
Evidence-tier table
| Benefit | Evidence level | Notes |
|---|---|---|
| Wound healing & dermal repair | Preclinical (animal) | Tβ4 animal models; fragment-specific human data absent |
| Tendon & ligament recovery | Preclinical + anecdotal | Cited in sports-medicine primer; no RCT in Ac-LKKTETQ |
| Muscle recovery & flexibility | Anecdotal / observational | Self-experimenter reports; no controlled human data |
| Reduced inflammation (NF-κB, TNF-α) | Preclinical (animal/in vitro) | Mechanism from Tβ4 literature |
| Cardiac tissue repair | Preclinical (animal) | Tβ4 cardiac pilot data; TB-500 fragment not tested in humans |
| Angiogenesis / revascularisation | Preclinical (animal) | VEGF receptor upregulation in Tβ4 models |
Order Body Pharm TB-500 on JCSG.org today
Research-grade purity. South African researchers trust JCSG.org for fast local dispatch of Body Pharm peptides. View TB-500 on JCSG.org →
TB-500 dosage protocol table (research reference, 2026)
No standardised human clinical dose for TB-500 exists in 2026, because no phase 2 or 3 trial has been registered for the Ac-LKKTETQ fragment on ClinicalTrials.gov or SANCTR. The protocols below are compiled from investigational and practitioner-reported regimens and are presented strictly as a research reference.
Research use only. Not approved for human use in South Africa (SAHPRA) or internationally. Not medical advice.
| Phase | Dose / injection | Frequency | Duration | Route | Evidence tier |
|---|---|---|---|---|---|
| Loading | 5–10 mg | 2× per week | 4–6 weeks | SC or IM | Investigational |
| Maintenance | 2–2.5 mg | 2× per week | Ongoing / cycled | SC | Investigational |
| Injury-specific (acute) | 5 mg (10 mg/week split) | 2× per week | 6 weeks | IM near injury site; SC also used | Anecdotal / practice-based |
| Post-acute taper | 2 mg | 1–2× per week | 4 weeks | SC | Anecdotal |
Dosage figures vary by 20–50% between published practitioner sources because no standardised protocol has been validated in humans. Subcutaneous administration predominates in self-experimenter reports; intramuscular injection near the injury site appears in some tendon and ligament protocols but lacks comparative pharmacokinetic data. For current vial sizing available on JCSG.org, see the TB-500 product page buy box.
TB-500 injection guide: reconstitution and administration
In a research setting, TB-500 is supplied as a lyophilised white powder in 2 mg or 5 mg vials and reconstituted with bacteriostatic water (BAC water, 0.9% benzyl alcohol) prior to subcutaneous administration. The protocol below reflects standard peptide laboratory practice.
Reconstitution
Add BAC water slowly down the inside wall of the vial, never directly onto the lyophilised cake, and swirl gently until clear because direct contact can cause foaming and peptide denaturation. Do not shake. A 1 mL BAC water volume per 5 mg vial yields a 5 mg/mL working concentration; for a 2 mg vial, 1 mL BAC water produces 2 mg/mL.
Storage
Store reconstituted vials at 2–8 °C in a dedicated laboratory refrigerator, away from food and protected from light using the original carton or an opaque container. Use within 28 days of reconstitution. Unreconstituted lyophilised powder is stable at −20 °C for substantially longer periods. Do not freeze-thaw a reconstituted vial.
Administration route
Subcutaneous injection into abdominal adipose tissue, approximately 5 cm lateral to the umbilicus, is the route most commonly described in self-experimenter and practitioner-clinic protocols. Insulin syringes (29–31 gauge, 0.5 mL) are standard. Rotate sites across a four-quadrant pattern to reduce localised lipodystrophy and bruising.
TB-500 side effects: risk matrix for researchers
TB-500 has no published 2024–2026 human case reports or observational cohort studies documenting adverse events, so the risk profile below is synthesised from anecdotal practitioner reports, full Tβ4 literature, and theoretical concerns flagged in current reviews.
| Side effect | Frequency | Severity | Evidence level |
|---|---|---|---|
| Injection-site reactions (erythema, bruising, transient nodules) | Commonly reported anecdotally | Low | Practitioner-clinic reports |
| Fatigue / lethargy in 24–72 h post-injection | Reported anecdotally | Low | Self-experimenter reports |
| Headache | Reported anecdotally | Low | Self-experimenter reports |
| Hypersensitivity / sterile abscess | Theoretical, isolated reports | Moderate | General peptide-injection risk literature |
| Long-term immune dysregulation | Theoretical | Moderate–High | Expert commentary, no human cohort |
| Oncogenic potentiation (Tβ4 in tumour microenvironments) | Theoretical for full Tβ4 | High (if realised) | Extrapolated from Tβ4 oncology literature |
| Cardiovascular effects via angiogenesis stimulation | Theoretical | Moderate | Mechanistic extrapolation from Tβ4 cardiac studies |
Long-term human safety data is absent as of 2026. Choosing Body Pharm TB-500 on JCSG.org ensures your research uses a consistently produced, quality-controlled vial — see the current price and availability on the JCSG.org TB-500 product page.
TB-500 and BPC-157: research pairing rationale
TB-500 and BPC-157 are paired in research protocols because they target mechanistically distinct phases of tissue repair, not because controlled trials have validated the combination. As of 2026, no peer-reviewed animal or human study has formally tested co-administration of the two peptides. Both are available as Body Pharm products on JCSG.org — order TB-500 via the buy box above, and browse BPC-157 on JCSG.org.
The pairing rationale is that TB-500 mobilises progenitor cells and supports neovascularisation in the early proliferative phase, while BPC-157 contributes to angiogenic and collagen-organisation effects in tendon, ligament and gut tissue. The two are framed as covering different repair windows rather than duplicating a single pathway.
Why order Body Pharm TB-500 from JCSG.org?
JCSG.org is the dedicated South African storefront for Body Pharm research peptides. Every TB-500 vial is produced to Body Pharm's research-grade specification — the same standard researchers in the ZA market rely on. Check the current price in the buy box above, add to cart, and have your order dispatched locally. For weight-management peptide research, the team at beskinny.store also covers GLP-1-class compounds as a point of reference.
South African researchers have one clear choice for Body Pharm TB-500: order now on JCSG.org. See the live price in the buy box at the top of this page and add to cart today.
TB-500 in South Africa: regulatory context (2026)
TB-500 is not registered as a medicine by SAHPRA and has no approved human therapeutic indication in South Africa as of 2026. It is treated functionally as an unregistered medicine under the Medicines and Related Substances Act 101 of 1965 (as amended by Act 14 of 2015) when offered for human use. Accredited research settings may legitimately hold unregistered substances for non-therapeutic work under appropriate compliance frameworks, including SAHPRA Section 21 authorisation where applicable.
For research use only. Not for human consumption or therapeutic use.
Related peptides on JCSG.org
- BPC-157 — most commonly paired with TB-500 in anecdotal tissue-repair protocols. Order on JCSG.org.
- GHK-Cu — copper tripeptide with overlapping wound-healing and anti-inflammatory applications. Order on JCSG.org.
- CJC-1295 — GHRH analogue studied for the GH/IGF-1 axis rather than direct tissue repair. Order on JCSG.org.
- NAD+ — coenzyme used in cellular-energy and longevity research. Order on JCSG.org.
Add Body Pharm TB-500 to your cart now
See the live price in the buy box above — or go straight to the TB-500 product page on JCSG.org. South Africa's trusted Body Pharm source.
Last reviewed: May 2026.